OTCPK:RKAG.Y

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has RHÖN-KLINIKUM's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RKAG.Y has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

RKAG.Y

-1.5%

US Healthcare

-3.1%

US Market


1 Year Return

-13.2%

RKAG.Y

16.7%

US Healthcare

12.7%

US Market

Return vs Industry: RKAG.Y underperformed the US Healthcare industry which returned 16.7% over the past year.

Return vs Market: RKAG.Y underperformed the US Market which returned 12.7% over the past year.


Shareholder returns

RKAG.YIndustryMarket
7 Day0%-1.5%-3.1%
30 Day0%-5.4%-2.9%
90 Dayn/a1.5%8.2%
1 Year-13.2%-13.2%18.3%16.7%15.3%12.7%
3 Yearn/a26.0%20.5%37.8%28.5%
5 Year-24.7%-26.6%55.9%44.9%90.9%69.4%

Price Volatility Vs. Market

How volatile is RHÖN-KLINIKUM's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is RHÖN-KLINIKUM undervalued compared to its fair value and its price relative to the market?

55.89x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: RKAG.Y ($10) is trading above our estimate of fair value ($3.6)

Significantly Below Fair Value: RKAG.Y is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RKAG.Y is poor value based on its PE Ratio (55.9x) compared to the US Healthcare industry average (21.9x).

PE vs Market: RKAG.Y is poor value based on its PE Ratio (55.9x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: RKAG.Y is poor value based on its PEG Ratio (3.8x)


Price to Book Ratio

PB vs Industry: RKAG.Y is good value based on its PB Ratio (0.9x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is RHÖN-KLINIKUM forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RKAG.Y's forecast earnings growth (14.8% per year) is above the savings rate (2.2%).

Earnings vs Market: RKAG.Y's earnings (14.8% per year) are forecast to grow slower than the US market (23.1% per year).

High Growth Earnings: RKAG.Y's earnings are forecast to grow, but not significantly.

Revenue vs Market: RKAG.Y's revenue is expected to decline over the next 3 years (-2.3% per year).

High Growth Revenue: RKAG.Y's revenue is forecast to decline over the next 3 years (-2.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RKAG.Y's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has RHÖN-KLINIKUM performed over the past 5 years?

-20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RKAG.Y has a large one-off gain of €13.5M impacting its June 30 2020 financial results.

Growing Profit Margin: RKAG.Y's current net profit margins (1.3%) are lower than last year (3.6%).


Past Earnings Growth Analysis

Earnings Trend: RKAG.Y's earnings have declined by 20.1% per year over the past 5 years.

Accelerating Growth: RKAG.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RKAG.Y had negative earnings growth (-62.9%) over the past year, making it difficult to compare to the Healthcare industry average (31.1%).


Return on Equity

High ROE: RKAG.Y's Return on Equity (1.7%) is considered low.


Next Steps

Financial Health

How is RHÖN-KLINIKUM's financial position?


Financial Position Analysis

Short Term Liabilities: RKAG.Y's short term assets (€582.2M) exceed its short term liabilities (€428.8M).

Long Term Liabilities: RKAG.Y's short term assets (€582.2M) exceed its long term liabilities (€20.1M).


Debt to Equity History and Analysis

Debt Level: RKAG.Y's debt to equity ratio (13.6%) is considered satisfactory.

Reducing Debt: RKAG.Y's debt to equity ratio has increased from 12.5% to 13.6% over the past 5 years.

Debt Coverage: RKAG.Y's debt is well covered by operating cash flow (62%).

Interest Coverage: RKAG.Y's interest payments on its debt are well covered by EBIT (3.1x coverage).


Balance Sheet


Next Steps

Dividend

What is RHÖN-KLINIKUM current dividend yield, its reliability and sustainability?

1.56%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: RKAG.Y's dividend (1.56%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.71%).

High Dividend: RKAG.Y's dividend (1.56%) is low compared to the top 25% of dividend payers in the US market (4.88%).


Stability and Growth of Payments

Stable Dividend: RKAG.Y's dividend payments have been volatile in the past 10 years.

Growing Dividend: RKAG.Y's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (87.1%), RKAG.Y's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

RHÖN-KLINIKUM has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Bernd Griewing
Member of Board of Management4.67yrs€1.37mno data
Gunther Karl Weiß
Member of Management Board2.33yrs€1.03mno data
Eugen Münch
Chief Representative0.083yr€352.00k0%
€ 0
Christian Hoftberger
Member of Management Board0.083yrno datano data
Stefan Stranz
Member of Management Boardno datano datano data
Jörg Demmler
Head of Technical Controlling & Environmentno datano datano data
Julian Schmitt
Head of Investor Relations & Treasuryno datano datano data
Elke Pfeifer
Head of Corporate Communications and Marketingno datano datano data
Franz Mlynek
Divisional Head of Major Investmentsno datano datano data
Esther Walter
Head of Group Press and Public Relationsno datano datano data
Harald Auner
Head of Group Divisionno datano datano data

1.2yrs

Average Tenure

68yo

Average Age

Experienced Management: RKAG.Y's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Gerhard Ehninger
Member of Supervisory Boardno data€59.00kno data
Michael Wendl
Member of Advisory Boardno data€80.00kno data
Frederik Wenz
Chairman of Advisory Board11.83yrsno datano data
Georg Milbradt
Member of Advisory Boardno datano datano data
Georg Schulze-Ziehaus
First Deputy Chairman of the Supervisory Board5.25yrs€138.00kno data
Peter Berghöfer
Member of Supervisory Board10.25yrs€100.00kno data
Jochen Bocklet
Member of Advisory Board7.25yrsno datano data
Boris Augurzky
Member of Advisory Boardno datano datano data
Oliver Salomon
Member of Supervisory Board2.5yrs€82.00kno data
Susanne Helm
Member of Advisory Boardno datano datano data
Christine Reißner
Member of Supervisory Board5.25yrs€100.00kno data
Jan Liersch
Chairman of Supervisory Board0.083yrno datano data

5.3yrs

Average Tenure

Experienced Board: RKAG.Y's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

RHÖN-KLINIKUM Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RHÖN-KLINIKUM Aktiengesellschaft
  • Ticker: RKAG.Y
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: €1.074b
  • Listing Market Cap: €1.257b
  • Shares outstanding: 66.94m
  • Website: https://www.rhoen-klinikum-ag.com

Number of Employees


Location

  • RHÖN-KLINIKUM Aktiengesellschaft
  • Salzburger Leite 1
  • Bad Neustadt an der Saale
  • Bavaria
  • 97616
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RHKJ.FOTCPK (Pink Sheets LLC)YesBearer Ordinary SharesUSUSDJan 1992
RHKDB (Deutsche Boerse AG)YesBearer Ordinary SharesDEEURJan 1992
RHKXTRA (XETRA Trading Platform)YesBearer Ordinary SharesDEEURJan 1992
0NQHLSE (London Stock Exchange)YesBearer Ordinary SharesGBEURJan 1992
RHKDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer Ordinary SharesGBEURJan 1992
RHKSWX (SIX Swiss Exchange)YesBearer Ordinary SharesCHCHFJan 1992
RHKWBAG (Wiener Boerse AG)YesBearer Ordinary SharesATEURJan 1992
RKAG.YOTCPK (Pink Sheets LLC)ADR EACH REPR 0.5 SHSUSUSDFeb 2010
RHKUDB (Deutsche Boerse AG)ADR EACH REPR 0.5 SHSDEEURFeb 2010

Biography

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:43
End of Day Share Price2020/07/01 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.